Methods of preparation, isolation and purification of recombinant interferon alfa-2b for medical applications RIGHTS

摘要

1. method u043fu043eu043bu0443u0447u0435u043du0438u00a0, u0432u044bu0434u0435u043bu0435u043du0438u00a0 and treatment with interferon alpha 2b, designed u0434u043bu00a0 u0438u0441u043fu043eu043bu044cu0437u043eu0432u0430u043du0438u00a0 medicine from the insoluble u0432u043au043bu044eu0447u0435u043du0438u00a0 u0440u0435u043au043eu043c taurus u0431u0438u043du0430u043du0442u043du044bu0445 cells culture.coli, including the destruction of bacterial cells, removal of cellular proteins, the body u0432u043au043bu044eu0447u0435u043du0438u00a0, u0441u043eu043bu044eu0431u0438u043bu0438u0437u0430u0446u0438u044e cells u0432u043au043bu044eu0447u0435u043du0438u00a0, recovery, u0440u0435u043du0430u0442u0443u0440u0430u0446u0438u044e and the u0445u0440u043eu043cu0430u0442u043eu0433u0440u0430u0444u0438u0447u0435u0441u043au0443u044e purified protein and its heat treatment, in which the removal of u043fu0440u0438u043cu0435u0441u043du044bu0445 proteins in the allocation of cells u0432u043au043bu044eu0447u0435u043du0438u00a0 u043fu0440u043eu0432u043eu0434u00a0u0442 buffering u0440u0430u0441u0442u0432u043eu0440u043e m containing u043cu043eu0447u0435u0432u0438u043du0443 and u0434u0435u0442u0435u0440u0433u0435u043du0442u044b,u0441u043eu043bu044eu0431u0438u043bu0438u0437u0430u0446u0438u044e tv u043fu0440u043eu0432u043eu0434u00a0u0442 6 m u0433u0443u0430u043du0438u0434u0438u043du0445u043bu043eu0440u0438u0434u043eu043c, recovery u0432u044bu043fu043eu043bu043du00a0u044eu0442 2 - u043cu0435u0440u043au0430u043fu0442u043eu044du0442u0430u043du043eu043bu043eu043c or u0434u0438u0442u0438u043eu0442u0440u0438u044du0442u043eu043bu043eu043c, u0440u0435u043du0430u0442u0443u0440u0430u0446u0438u044e IF2b u043fu0440u043eu0432u043eu0434u00a0u0442 u0440u0430u0437u0431u0430u0432u043bu0435u043du0438u0435u043c u0432u043eu0441u0441u0442u0430u043du043eu0432u043b u0435u043du043du043eu0433u043e protein by neutral or weak alkali buffer with ph 8.0 8.6 to total protein concentration of 0.04 and 0.10 mg / ml at 4c for 24 to 48 hours.u0445u0440u043eu043cu0430u0442u043eu0433u0440u0430u0444u0438u0447u0435u0441u043au0443u044e cleaning u043fu0440u043eu0432u043eu0434u00a0u0442 first u0430u043du0438u043eu043du043eu043eu0431u043cu0435u043du043du043eu043c u0441u043eu0440u0431u0435u043du0442u0435 at ph 8.0 and 8.5, with subsequent u044du043bu044eu0446u0438u0435u0439 buffer with ph 8.5 in the presence of 0.3 m chloride u043du0430u0442u0440u0438u00a0, u043fu043eu0434u043a u0438u0441u043bu0435u043du0438u0435 protein solution to u0437u043du0430u0447u0435u043du0438u00a0 ph 4.6, and then u043au0430u0442u0438u043eu043du043eu043eu0431u043cu0435u043du043du043eu043c u0441u043eu0440u0431u0435u043du0442u0435 at ph 4.6, 5.0 and subsequent u044du043bu044eu0446u0438u0435u0439 buffer with ph 4.6 with 0.3 m chloride u043du0430u0442u0440u0438u00a0.;2. method for 1, in which after heat treatment may u0445u0440u043eu043cu0430u0442u043eu0433u0440u0430u0444u0438u0447u0435u0441u043au043eu0439 cleaning IF2b u043fu0440u043eu0432u043eu0434u0438u0442u0441u00a0 protein in the presence of u043eu043au0438u0441u043bu00a0u044eu0449u0438u0445 substances u0434u043bu00a0 u0443u0434u0430u043bu0435u043du0438u00a0 u043eu043bu0438u0433u043eu043cu0435u0440u043eu0432 IF2b and e the forms, is formed in the process of u0440u0435u043du0430u0442u0443u0440u0430u0446u0438u0438.